Lutetium-177-labelled bombesin analogue

Drug Profile

Lutetium-177-labelled bombesin analogue

Alternative Names: 177Lu-AMBA

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bracco
  • Developer Bracco; Marillion Pharmaceuticals
  • Class Lanthanoid series elements; Peptide hormones
  • Mechanism of Action Bombesin receptor agonists; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Breast cancer; Prostate cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Prostate-cancer in Europe (IV)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Breast-cancer(Late-stage disease, Metastatic disease) in USA (IV)
  • 12 Nov 2008 Lutetium-177-labelled bombesin analogue licensed to Marillion Pharmaceuticals worldwide for the treatment of hormone-resistant prostate and metastatic breast cancers
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top